Format

Send to

Choose Destination
HIV Clin Trials. 2013 Mar-Apr;14(2):75-9. doi: 10.1310/hct1402-75.

High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine.

Author information

1
Division of Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA. tiw2001@med.cornell.edu

Abstract

PURPOSE:

High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer.

METHODS:

We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN.

RESULTS:

HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P = .01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN.

CONCLUSION:

HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.

PMID:
23611828
PMCID:
PMC3676177
DOI:
10.1310/hct1402-75
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center